MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,666.45
+0.19%
NASDAQ 100
$30,501.56
+0.31%
DOW JONES
$50,927.00
+0.04%
NASDAQ Composite
$26,871.60
+0.04%
RUSSELL 2000
$2,790.20
+0.41%
CBOE VIX
$16.39
+0.31%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
ANTX — AN2 Therapeutics, Inc. Common Stock
NasdaqAN2 Therapeutics, Inc. Common Stock
$5.71
+0.09(+1.60%)
- O
- 5.64
- H
- 5.99
- L
- 5.51
- V
- 451.28K
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About ANTX
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateMar 25, 2022
Employees21
Stock ExchangeNasdaq
Ticker SymbolANTX
Key Financial Statistics
| Market Cap | $184.15M |
| P/E Ratio | N/A |
| Dividend Yield | N/A |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $0.87 - $23.58 |
| 52-Week Avg Volume | 253.6K |
| VWAP | $5.74 |
| Transactions | 5,175 |
| Total Recorded Bars | 1,135 days |